Automated Adaptive Trial Design Simulation and Protocol Writing Workflow

Adaptive trial designs—like sample size re-estimation or arm dropping—offer significant efficiency gains but require intensive statistical simulation and precise protocol authoring. Traditionally, this involves months of biostatistician labor, iterative scenario modeling, and manual drafting, creating a major bottleneck in trial setup. A custom automation workflow directly addresses this by ingesting trial objectives and historical data to run thousands of simulations, rank design options by power and feasibility, and draft the corresponding statistical and methods sections, compressing a quarter of work into days.

Implementation requires a multi-agent architecture. An orchestrator, built with LangGraph, manages the flow from data ingestion in SAS or R to simulation execution. A drafting agent, using retrieval-augmented generation (RAG) against ICH E9 and sponsor templates, authors the protocol. Critical controls include a human-in-the-loop review gate for the selected design and all statistical text, plus full audit trails of simulation parameters and drafting rationale for regulatory defensibility. This system reduces statistical consultancy time by over 60% and improves design quality through exhaustive scenario testing.

This workflow automates the high-cost bottleneck of modeling complex adaptive designs—like sample size re-estimation or arm dropping—and translating them into executable protocol language. It eliminates weeks of manual simulation and drafting by statistical and medical teams. The operational upside comes from compressing design iteration cycles, reducing reliance on external consultants, and producing statistically sound, regulator-ready documents faster, directly accelerating trial setup and improving resource allocation.

Implementation integrates a LangGraph-based orchestrator that sequences specialized simulation and authoring agents. The simulation engine, built on platforms like SAS or R, runs thousands of design iterations. Results feed an authoring agent that drafts the statistical methodology, stopping rules, and analysis sections. The workflow enforces governance through a validation layer that checks outputs against a statistical rule base and regulatory guidelines (ICH E9, FDA Adaptive Design guidance) before routing to a medical reviewer in Veeva Vault. This architecture ensures auditability, manages exception routing for novel designs, and connects directly to document management systems for version control.

This workflow automates the high-cost bottleneck of designing and documenting complex adaptive trials. It ingests historical trial data, target product profiles, and regulatory constraints to simulate thousands of design scenarios—evaluating sample size re-estimation, arm dropping, and Bayesian stopping rules. The operational upside comes from compressing months of statistical modeling into days, directly reducing external consultancy fees and accelerating protocol finalization. The architecture begins with a secure data ingestion layer connecting to internal data lakes and external databases like Citeline or TrialTrove.

Implementation proceeds in controlled phases. Phase 1 deploys the simulation engine behind a review gateway, allowing biostatisticians to validate model outputs. Phase 2 integrates the authoring agent, initially drafting supplementary documents before progressing to core protocol text. Critical controls include mandatory human sign-off on all statistical assumptions and protocol changes, with a full audit trail logged to the document management system. The final orchestration layer, built with LangGraph or a custom Python service, manages data flow between the simulation cluster, drafting modules, and enterprise systems, ensuring version control and enabling rollback.

This custom workflow automates the high-latency, expert-dependent process of simulating adaptive design scenarios—like sample size re-estimation or arm dropping—and translating them into rigorous protocol text. It directly reduces statistical consultancy time by weeks per trial and improves operational efficiency by enabling rapid iteration on design trade-offs before protocol finalization. The architecture ingests target product profiles, historical trial data, and regulatory constraints to power simulation engines, with outputs feeding a specialized drafting agent.

Implementation connects simulation platforms (e.g., R, SAS) via API to an LLM orchestrator like LangGraph, which manages the drafting agent, validation rules, and human review queues. The system writes directly into protocol templates within systems like Veeva Vault, embedding statistical rationale and simulation summaries. Critical controls include pre-approval of simulation parameters, mandatory human review of novel design elements, and full audit trails of all design decisions and generated text to satisfy regulatory scrutiny.

This workflow directly addresses the operational bottleneck of manually simulating adaptive scenarios—like sample size re-estimation or arm dropping—which requires extensive biostatistician time and delays protocol finalization. The automation ingests target product profiles and historical trial data into a simulation engine, running thousands of design permutations to optimize for power, sample size, and cost. The resulting statistical plan is then passed to a protocol-drafting agent, which authors the Methods and Statistical Considerations sections, ensuring alignment between the simulated design and the executable document.

Implementation integrates the simulation engine with clinical data standards (CDISC) and document management systems like Veeva Vault or SharePoint. The orchestrator, built on LangGraph, manages the data flow, exception routing for statistically invalid designs, and sequential approval gates. Controls include pre-commit validation of statistical assumptions, version tracking for auditability, and mandatory human sign-off on final adaptive rules and stopping boundaries before the protocol is locked, ensuring regulatory defensibility.